Deal Watch: Pfizer/AstraZeneca Lead Pack Of Takeover Efforts
Executive Summary
Pfizer’s new, increased offer for AstraZeneca on May 2 was rejected swiftly by the U.K.’s second-largest pharmaceutical company. But other companies’ acquisitive strategies have been more successful this week, with Forest announcing plans to acquire Furiex, Bristol buying out one-asset biotech iPierian, and Endo nabbing the privately owned Mexican specialty company, Somar.